XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUE Disaggregated Revenue Table (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Disaggregation of Revenue [Line Items]      
Accounts Receivable, Allowance for Credit Loss $ 34.2   $ 32.7
Unbilled Services, Allowance for Credit Loss 7.4   7.5
Note Receivable, Allowance for Credit Loss 0.7   0.7
Allowance for Credit Loss 42.3   40.9
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings 2.4    
Allowance for Credit Loss, Write Off 1.0    
Deferred Revenue, Revenue Recognized 51.0 $ 52.6  
Contract with Customer, Asset, before Allowance for Credit Loss 127.8   192.9
Contract with Customer, Liability 377.5   421.7
Unbilled Contracts Receivable $ 120.4   185.4
Percent of Revenue Contributed 100.00% 100.00%  
Revenues $ 3,176.6 $ 3,037.8  
Accounts Receivable, after Allowance for Credit Loss, Current 2,083.7   1,913.3
Allowance for Credit Loss, Receivable, Other, Current (7.4)   (7.5)
Contract with Customer, Asset, after Allowance for Credit Loss, Current $ 120.4   185.4
Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 9.00% 9.00%  
North America      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 87.00% 87.00%  
Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 4.00% 4.00%  
UNITED STATES      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 83.60% 84.20%  
Revenues $ 2,654.6 $ 2,557.4  
Medicare and Medicaid [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 8.00% 8.00%  
LabCorp Diagnostics [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 78.00% 78.00%  
LabCorp Diagnostics [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | North America      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 78.00% 78.00%  
LabCorp Diagnostics [Member] | Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Client [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 25.00% 25.00%  
LabCorp Diagnostics [Member] | Client [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Client [Member] | North America      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 25.00% 25.00%  
LabCorp Diagnostics [Member] | Client [Member] | Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 10.00% 9.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member] | North America      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 10.00% 9.00%  
LabCorp Diagnostics [Member] | Self-Pay [Member] | Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | North America      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 8.00% 8.00%  
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Third party [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 35.00% 36.00%  
LabCorp Diagnostics [Member] | Third party [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
LabCorp Diagnostics [Member] | Third party [Member] | North America      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 35.00% 36.00%  
LabCorp Diagnostics [Member] | Third party [Member] | Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 0.00% 0.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed   22.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed   9.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | North America      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed   9.00%  
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed   4.00%  
Diagnostics      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 78.00%    
Accounts Receivable, before Allowance for Credit Loss $ 1,260.9   1,135.2
Drug Development      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 22.00%    
Accounts Receivable, before Allowance for Credit Loss $ 857.0   $ 810.8
Drug Development | Biopharmaceutical and medical device companies [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 22.00%    
Drug Development | Biopharmaceutical and medical device companies [Member] | Europe [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 9.00%    
Drug Development | Biopharmaceutical and medical device companies [Member] | North America      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 9.00%    
Drug Development | Biopharmaceutical and medical device companies [Member] | Other countries [Member]      
Disaggregation of Revenue [Line Items]      
Percent of Revenue Contributed 4.00%    
Notes Receivable [Member]      
Disaggregation of Revenue [Line Items]      
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings $ 0.0    
Allowance for Credit Loss, Write Off 0.0    
Unbilled Contracts Receivable [Member]      
Disaggregation of Revenue [Line Items]      
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings 0.0    
Allowance for Credit Loss, Write Off 0.1    
Accounts Receivable [Member]      
Disaggregation of Revenue [Line Items]      
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings 2.4    
Allowance for Credit Loss, Write Off $ 0.9